Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis

American Journal of Health-System Pharmacy

Volumn 64, Issue 8, 2007, Pages 830-836

  Baker, William L ^a,b   Couch, Kimberly A ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Azithromycin; Coronary disease; Macrolides; Mortality; Outcomes

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 34247262005     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060539     Document Type: Article

References (32)

1. American Heart Association. 2006 heart and stroke statistical update. Dallas, TX: American Heart Association; 2006.
2. Ramirez IA, Ahkee S, Summersgill IT et al. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Arch Intern Med. 1996; 125:979-82.
3. Mendall MA, Carrington D, Strachan D et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995; 30:121-8.
4. Mass M, Bartels C, Engle P et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998; 31:827-32.
5. Danesh I, Collins R, Peto R. Chronic infection and coronary heart disease: is there a link? Lancet. 1997; 350:430-6.
6. Muhlestein JB, Hammond EH, Carlquist IF et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996; 27:1555-61.
7. Zhu J, Nieto J, Home BD et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001; 103:45-51.
8. Sander D, Winbeck K, Klingelhofer J et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002; 106:2428-33.
9. Liu R, Yamamoto M, Moroi M et al. Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology. Am Heart J. 2005; 150:681-8.
10. Danesh J, Whincup P, Walker M et al. Chlamydia pneumoniae IgG titres and coronary disease: prospective study and meta-analysis. BMJ. 2000; 321:208-13.
11. Gupta S, Leatham EW, Carrington D et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation. 1997; 96:404-7.
12. Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000; 102:1755-60.
13. O'Connor CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study, a randomized controlled trial. JAMA. 2003; 290:1459-66.
14. Grayston JT, Kronmal R, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005; 352:1637-45.
15. Gurfinkel E, Bozovich G, Beck E et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J. 1999; 20:121-7.
16. Cannon CP, Braunwald E, McCabe CH et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005; 351:1646-54.
17. Cercek B, Shah PK, Noc M et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomized controlled trial. Lancet. 2003; 361:809-13.
18. Zahn R, Schneider S, Frilling B et al. Antibiotic Therapy After Acute Myocardial Infarction (ANTIBIO): a prospective randomized trial. Circulation. 2003; 107:1253-9.
19. Stone AF, Mendall MA, Kaski JC et al. Effect of the treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002; 106:1219-23.
20. Sinisalo I, Manila K, Valtonen V et al. Clarithromycin in acute coronary syndrome patients in Finland (CLARIFY) study group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002; 105:1555-60.
21. Leowattana W, Bhuripanyo K, Singhaviranon L et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai. 2001; 84(suppl 3):S669-75.
22. Top 200 brand-name drugs by retail dollars in 2005. Drug Topics. 2006; Mar 6:28.
23. Jadad AR, Moore A, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-88.
25. Roblin PM, Hammershlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin in isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother. 1998; 42:194-6.
26. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother. 1998; 42:2762-4.
27. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998; 97:633-6.
28. Hyodo E, Hozumi T, Takemoto Y et al. Effect of azithromycin therapy on coronary circulation in patients with coronary artery disease. Am J Cardiol. 2004; 94:1426-9.
29. Hillis GS, Pearson CV, Harding SA et al. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study. Am Heart J. 2004; 148:72-9.
30. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002; 105:1298-1303.
31. Wells BJ, Mainous AG, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004; 164:2156-61.
32. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005; 293:2641-7.